KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Other Non Operating Income (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Other Non Operating Income for 16 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income fell 66.5% to $2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.5 million through Dec 2025, down 9.6% year-over-year, with the annual reading at $21.5 million for FY2025, 9.6% down from the prior year.
  • Other Non Operating Income for Q4 2025 was $2.4 million at Halozyme Therapeutics, down from $5.3 million in the prior quarter.
  • The five-year high for Other Non Operating Income was $7.3 million in Q4 2024, with the low at -$945000.0 in Q2 2022.
  • Average Other Non Operating Income over 5 years is $3.2 million, with a median of $3.1 million recorded in 2023.
  • The sharpest move saw Other Non Operating Income tumbled 527.6% in 2022, then soared 646.65% in 2023.
  • Over 5 years, Other Non Operating Income stood at $331000.0 in 2021, then surged by 157.4% to $852000.0 in 2022, then surged by 529.11% to $5.4 million in 2023, then surged by 35.32% to $7.3 million in 2024, then crashed by 66.5% to $2.4 million in 2025.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at $2.4 million, $5.3 million, and $6.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.